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The reduction in breast cancer mortality during the past
20 years can be partly explained by increased use of
adjuvant endocrine therapy. During recent years a number of
studies have explored potential benefits of aromatase
inhibitors (AIs) over tamoxifen for postmenopausal women
with oestrogen receptor-positive breast cancer. Early results,
which reported improved disease-free survival with AIs, led
to a recommendation by the American Society of Clinical
Oncology technology assessment panel in 2005 that the
treatment of these women should include an AI, either as
initial (up-front) therapy or following a period of treatment
with tamoxifen [1]. Despite the improved disease-free
survival with AIs, a recent review of up-front use of AIs failed
to show any evidence of significant improvement in overall
survival over tamoxifen, or in quality of life, and advised
caution for use of this strategy pending future results from
the BIG 1-98 clinical trial [2].
Professor Ian Smith presented results from BIG 1-98
comparing 5 years of letrozole with tamoxifen. These results,
first presented at the San Antonio Breast Cancer
Symposium in 2008 [3], show no statistically significant
overall survival benefit for Letrozole at 76 months follow up.
These results support a recent meta-analyses of AI use that
showed no evidence of a significant overall survival
advantage when AIs are used up front [4]. In fact, the only AI
studies that demonstrate an overall survival advantage to
date involve switching to an AI after initial therapy with
tamoxifen [5]. Current American Society of Clinical
Oncology guidelines, and recent National Institute of Clinical
Excellence guidelines, allow clinicians to decide whether to
pursue an up-front approach to AI use or whether to adopt a
switching strategy.
Professor Ian Smith also presented a summary of results from
the Z-FAST and ZO-FAST studies, comparing the effects of
zoledronic acid initiated concurrently with letrozole or when
bone loss becomes clinically significant in postmenopausal
women with early breast cancer. An integrated analysis of
both studies [6] suggests that up-front use of zoledronic acid
is an effective strategy to prevent AI-associated bone loss,
when given in combination with letrozole for postmenopausal
women, and in addition appears to reduce the risk of breast
cancer recurrence. Although the recurrence data require
further follow up, these early results would support a change
in the 2009 National Institute of Clinical Excellence guidelines.
Professor Mike Dixon presented data on the number of
mastectomies currently performed for early breast cancer in
the UK using data from the NHS Breast Screening Pro-
gramme. He suggested that although the mastectomy rate for
screen-detected ductal carcinoma in situ has remained fairly
constant in recent years, the massive increase in the numbers
of women diagnosed with ductal carcinoma in situ means
that overall the number of mastectomies has increased. In his
opinion, as ductal carcinoma in situ is a unifocal disease it
may be possible to avoid mastectomy in a large number of
cases, although increased use of oncoplastic techniques will
be required for more extensive resections. Alternative strate-
gies could include preoperative neoadjuvant hormone therapy
or preoperative HER2 blockade.
Finally, Professor Dixon presented a summary of the COMICE
study, where patients recommended to have breast-
conserving surgery were randomised to have breast magnetic
resonance imaging or not. In this study, magnetic resonance
imaging caused a significant increase in the mastectomy rate
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(13% vs. 9%) but did not reduce the re-excision rate; as a
result, routine use of magnetic resonance imaging for all
women having breast-conserving surgery is not currently
recommended.
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